About Candel

The cancer treatment paradigm has shifted dramatically over the last decade, providing evidence that the immune system can be reactivated against a patient’s tumor. The mechanism of action of oncolytic viral immunotherapies is unique in combining both an anti-tumor cytotoxic component and an immune-stimulatory component. Together, these modalities lead to an “in-situ vaccination” effect against the tumor.

At Candel Therapeutics, we are developing immunotherapies that induce immunogenic cell death in cancer cells at the site of injection, unmasking tumor neo-antigens within an activated microenvironment. This process leads to a systemic, durable immune response against the tumor, with the potential to change disease outcomes across a variety of indications.

Candel’s products are designed to improve survival while maintaining quality of life – from early- to late-stage disease.

Our PURPOSE

to save, extend and improve the lives of patients through oncolytic viral immunotherapies.

Our PLAN

to harness the power of our proprietary virus-based approaches and elicit a broad, potent immune response against solid tumors and their metastases.

OUR LEADERSHIP

is made up of renowned drug developers, oncolytic viral immunotherapy experts, oncologists, immunologists and biotech business leaders. Candel is built on science, and our experienced team is helping translate its full promise to patients.

BOARD OF DIRECTORS

RESEARCH ADVISORY BOARD

James P. Allison, Ph.D.

Chief of the Department of Immunology
MD Anderson Cancer Center
Director of the Parker Institute for Cancer Research

Henry Brem, M.D.

Director, Department of Neurosurgery
Professor of Neurosurgery
Johns Hopkins University

SCIENTIFIC ADVISORS

Adam Kibel, M.D.

Chief, Division of Urology Brigham and Women’s Hospital and Professor, Harvard Medical School

Steven M. Albelda, M.D.

Professor of Medicine and Vice Chief, Pulmonary, Allergy and Critical Care Division, Thoracic Research Laboratory, University of Pennsylvania​

Tri Le, M.D.

Assistant Professor, Medicine, Hematology and Oncology, University of Virginia

Patrick Y. Wen, M.D.

Director, Center for Neuro-Oncology Dana-Farber Cancer Institute and Professor, Neurology, Harvard Medical School

Scott Eggener, M.D.

Professor of Surgery and Radiology, Vice Chair of Urology, Director High Risk and Advanced Prostate Cancer Clinic, University of Chicago
© 2021 by Candel Therapeutics